Carbon Credit

A flexible lending arrangement that allows a borrower to draw down, repay, and redraw funds up to an agreed credit limit over the life of the facility, paying interest only on the amount outstanding plus a commitment fee on the undrawn portion. Revolving credit facilities are the primary source of working capital flexibility for corporate borrowers and are typically secured by a floating charge over the borrower's assets.

An autonomous software system that uses artificial intelligence to perceive its environment, make decisions, and take actions to achieve specified goals with minimal human intervention. AI agents are increasingly deployed in customer service, workflow automation, and decision support, and represent a growing category of operational intangible asset.

A decline in the expected rate of return on an asset class or investment, typically driven by increased demand, lower interest rates, or excess capital supply. Yield compression in private markets can inflate the implied valuations of intangible-heavy businesses, requiring investors to scrutinise whether premium multiples are supported by genuine intangible asset quality.

A fee paid by the acquiring bank to the issuing bank each time a payment card transaction is processed, representing the largest component of the merchant discount rate. Interchange fees are set by card networks (Visa, Mastercard) and vary by card type, merchant category, transaction method (card-present vs card-not-present), and jurisdiction.

The regulatory authorisation granted by the US Food and Drug Administration permitting a medical device to be marketed in the United States, typically through the 510(k) premarket notification pathway for devices that are substantially equivalent to an existing legally marketed device. FDA clearance is distinct from FDA approval (required for higher-risk Class III devices via the Premarket Approval pathway) and represents a significant regulatory intangible asset.

A market approach valuation technique that estimates the value of a subject company by reference to the trading multiples of publicly listed companies with similar business characteristics. The method involves identifying comparable public companies, selecting appropriate valuation multiples (such as EV/EBITDA or P/E), making adjustments for differences in size, growth, risk, and marketability, and applying the adjusted multiples to the subject company's financial metrics.

The EU regulatory framework (Regulation 2017/745) governing the design, manufacture, and distribution of medical devices in the European market, which replaced the Medical Devices Directive (93/42/EEC) with significantly stricter requirements. MDR imposes enhanced clinical evidence requirements, more rigorous conformity assessment procedures, a Unique Device Identification system, and comprehensive post-market surveillance obligations.

An AI architecture that combines a large language model with an external knowledge retrieval system, enabling the model to ground its responses in verified, up-to-date information rather than relying solely on its training data. RAG reduces hallucination risk, improves factual accuracy, and allows organisations to deploy AI systems that reference proprietary knowledge bases without retraining the underlying model.